INS and type 1 diabetes mellitus: VC-01 (consisting of the combination of PEC-01 cells and PEC-Encap device) was meant to be evaluated in an open-label, dose-escalating Phase 1/2 study in T1D patients with minimal insulin-producing β-cell function.